Altamira Medica

Protection against airborne allergens and viruses

Development status

Development of Bentrio™ (AM-301) has been completed. The product is about to be introduced to the market, starting in countries of the European Union.

Overview of key studies

StudyStudy designStatus
SARS-CoV-2 protection in human nasal epithelium cells

Daily treatment with Bentrio™ for 4 days starting 10 minutes prior to inoculation

Completed
SARS-CoV-2 treatment in human nasal epithelium cells

Daily treatment with Bentrio™ for 4 days starting 24 or 30 hours after inoculation

Completed
Prevention / treatment of H1N1 infection in human nasal epithelium cells

Daily treatment with Bentrio™ for 4 days starting after inoculation

Ongoing
Protection against symptoms of allergic rhinitis under grass pollen challenge
Exposure of patients with history of allergic rhinitis to grass pollen for four hours, treated prior with either Bentrio™ or HPMC power nasal spray (n=36)
Completed
Prevention / treatment of SARS-CoV-2

Treatment of patients with confirmed Covid-19 and non-infected household members with Bentrio™ or placebo (n=592)

Planned

Preclinical and clinical evidence

Preventive use of Bentrio™ reduces SARS-CoV-2 titer by up to 99.4%.

Mean viral titer in Vero cells over four days following inoculation of human nasal epithelium cells with SARS-CoV-2. Treatment with saline solution (control), AM-301 (Bentrio™) or AM-301 without key component (matrix) started 10 minutes prior to inoculation and continued once daily. Compared to the saline control group, Bentrio™ achieved a reduction in viral titer of >99% on Days 3 and 4. Even when unbound virus was not removed daily through washing, the reduction in viral titer was >92.4% compared to saline-treated controls.

Bentrio™ alleviates allergic rhinitis symptoms.

Mean change in the Total Nasal Symptom Score (TNSS) during stay of study participants with history of allergic rhinitis in grass pollen challenge chamber. A single dose of Bentrio™ applied into each nostril  prior to entering the chamber provided for a significant reduction in the self-rated TNSS. 

Current clinical investigations

There are currently no clinical investigations enrolling participants.

© Altamira Therapeutics

Diese E-Mail-Adresse ist vor Spambots geschützt! Zur Anzeige muss JavaScript eingeschaltet sein!